European Commission says: ELF is leading the way to discovering new medicines
MI’s European Lead Factory project has created an integrated platform which is providing an innovative range of free services, expertise and a huge collection of compounds for researchers who are developing new drugs to treat all types of human diseases.
Significant contributions:
The project consortium comprises 30 partners, including academic institutions, small and medium-sized enterprises (SMEs) and pharmaceutical companies. The team also includes seven members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) who decided to open up their previously secret compound libraries to kick-start early-stage research into discovering new medicines.
The EFPIA has contributed more than 300 000 compounds to the project’s Joint European Compound Library (JECL), while a further 200 000 compounds – specifically synthesised for the JECL – are being provided by SMEs. As of December 2017, JECL already contained 500 095, taking it over the target of 500 000 set at the start of the project.
Researchers can have their target programmes screened at facilities run by the project’s own European screening centre. They are given access to a selected number of compounds with the highest potential for further development at the researcher’s own initiative – or possibly in collaboration with EFPIA partners.
The library and screening services are already delivering concrete results. More than 4 500 compounds have made it through the screening process and have been handed over to European academics and SMEs for use in drug-development programmes.
Read the full press success story here.
About Taros Chemicals
Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.
Press Contact:
Youri R. Mesmoudi, Executive Vice President, e-mail: innovation |at| taros.de
Drug Discovery
Taros’ international and multidisciplinary team has more than 180 years of pharmaceutical R&D experience. Collectively as a team, we worked on more than 120 biomolecular…
Material Science
We create performance chemicals to enhance new materials, plastics, coatings, dyes & inks, cosmetics, flavors and many more research and industrial applications…
